- Home
- Publications
- Publication Search
- Publication Details
Title
Role of PTEN, PI3K, and mTOR in Triple-Negative Breast Cancer
Authors
Keywords
-
Journal
Life-Basel
Volume 11, Issue 11, Pages 1247
Publisher
MDPI AG
Online
2021-11-17
DOI
10.3390/life11111247
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Friend or foe: ABCG2, ABCC1 and ABCB1 expression in triple-negative breast cancer
- (2021) Milica Nedeljković et al. Breast Cancer
- Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer
- (2021) Chao Dong et al. Frontiers in Pharmacology
- Targeting Protein Synthesis in Colorectal Cancer
- (2020) Stefanie Schmidt et al. Cancers
- PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers
- (2020) Rui Liu et al. Cell Death & Disease
- PUF60 accelerates the progression of breast cancer through down-regulation of PTEN expression
- (2019) Dongying Sun et al. Cancer Management and Research
- PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside
- (2019) Ali S. Alzahrani SEMINARS IN CANCER BIOLOGY
- PTEN Tumor-Suppressor: The Dam of Stemness in Cancer
- (2019) Francesca Luongo et al. Cancers
- Mechanisms of Chemotherapy Resistance in Triple-Negative Breast Cancer—How We Can Rise to the Challenge
- (2019) Nedeljković et al. Cells
- Evaluation of the prognostic stage in the 8th edition of the American Joint Committee on Cancer in locally advanced breast cancer: An analysis based on SEER 18 database
- (2018) Maoli Wang et al. BREAST
- Comparison of AJCC Anatomic and Clinical Prognostic Stage Groups in Breast Cancer: Analysis of 3322 Cases from a Single Institution
- (2018) Ashish Kurundkar et al. Clinical Breast Cancer
- Loss of PTEN in high grade advanced stage triple negative breast ductal cancers in African American women
- (2018) Farhan Khan et al. PATHOLOGY RESEARCH AND PRACTICE
- Comparison of Pathological Prognostic Stage and Anatomic Stage Groups According to the Updated Version of the American Joint Committee on Cancer (AJCC) Breast Cancer Staging 8th Edition
- (2018) Kamuran Ibis et al. MEDICAL SCIENCE MONITOR
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Genetic Markers in Triple-Negative Breast Cancer
- (2018) Zuzana Sporikova et al. Clinical Breast Cancer
- 5-Oxo-hexahydroquinoline derivatives as modulators of P-gp, MRP1 and BCRP transporters to overcome multidrug resistance in cancer cells
- (2018) Sara Ranjbar et al. TOXICOLOGY AND APPLIED PHARMACOLOGY
- Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
- (2017) Sung-Bae Kim et al. LANCET ONCOLOGY
- Clinical value of CagA, c‑Met, PI3K and Beclin‑1 expressed in gastric cancer and their association with prognosis
- (2017) Xiaojun Huang et al. Oncology Letters
- Triple negative breast cancer: the kiss of death
- (2017) Adriana-Andreea Jitariu et al. Oncotarget
- Partial PTEN deletion is linked to poor prognosis in breast cancer
- (2015) P. Lebok et al. BMC CANCER
- Loss of PTEN expression is associated with aggressive behavior and poor prognosis in Middle Eastern triple-negative breast cancer
- (2015) Shaham Beg et al. BREAST CANCER RESEARCH AND TREATMENT
- A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer
- (2015) Thomas U. Ahearn et al. JNCI-Journal of the National Cancer Institute
- A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer
- (2015) Thomas U. Ahearn et al. JNCI-Journal of the National Cancer Institute
- Comprehensive analysis of PTEN status in breast carcinomas
- (2013) Natalie Jones et al. INTERNATIONAL JOURNAL OF CANCER
- Cytokeratin 5/6, c-Met expressions, and PTEN loss prognostic indicators in triple-negative breast cancer
- (2013) Mevlude Inanc et al. MEDICAL ONCOLOGY
- mTOR Signaling in Growth Control and Disease
- (2012) Mathieu Laplante et al. CELL
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- PI3K expression and PIK3CA mutations are related to colorectal cancer metastases
- (2012) Yu-Fen Zhu WORLD JOURNAL OF GASTROENTEROLOGY
- The expression and clinical significance of PI3K, pAkt and VEGF in colon cancer
- (2012) YINXU ZHANG et al. Oncology Letters
- mTOR in breast cancer: Differential expression in triple-negative and non-triple-negative tumors
- (2011) S. Walsh et al. BREAST
- Deciphering the Role of PI3K/Akt/mTOR Pathway in Breast Cancer Biology and Pathogenesis
- (2010) Priscilla F. McAuliffe et al. Clinical Breast Cancer
- Metastatic Behavior of Breast Cancer Subtypes
- (2010) Hagen Kennecke et al. JOURNAL OF CLINICAL ONCOLOGY
- Triple-Negative Breast Cancer
- (2010) William D. Foulkes et al. NEW ENGLAND JOURNAL OF MEDICINE
- An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer
- (2008) K. Stemke-Hale et al. CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started